JP2021534769A5 - - Google Patents

Info

Publication number
JP2021534769A5
JP2021534769A5 JP2021510191A JP2021510191A JP2021534769A5 JP 2021534769 A5 JP2021534769 A5 JP 2021534769A5 JP 2021510191 A JP2021510191 A JP 2021510191A JP 2021510191 A JP2021510191 A JP 2021510191A JP 2021534769 A5 JP2021534769 A5 JP 2021534769A5
Authority
JP
Japan
Prior art keywords
cancer
polypeptide
cell
antigen
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534769A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048921 external-priority patent/WO2020047326A2/en
Publication of JP2021534769A publication Critical patent/JP2021534769A/ja
Publication of JP2021534769A5 publication Critical patent/JP2021534769A5/ja
Pending legal-status Critical Current

Links

JP2021510191A 2018-08-31 2019-08-29 デコイポリペプチド Pending JP2021534769A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725977P 2018-08-31 2018-08-31
US62/725,977 2018-08-31
PCT/US2019/048921 WO2020047326A2 (en) 2018-08-31 2019-08-29 Decoy polypeptides

Publications (2)

Publication Number Publication Date
JP2021534769A JP2021534769A (ja) 2021-12-16
JP2021534769A5 true JP2021534769A5 (enExample) 2022-09-06

Family

ID=67997686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510191A Pending JP2021534769A (ja) 2018-08-31 2019-08-29 デコイポリペプチド

Country Status (5)

Country Link
US (1) US20210347848A1 (enExample)
EP (1) EP3843772A2 (enExample)
JP (1) JP2021534769A (enExample)
MA (1) MA53493A (enExample)
WO (1) WO2020047326A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
WO2021108693A1 (en) 2019-11-27 2021-06-03 ALX Oncology Inc. Combination therapies for treating cancer
JP2023528341A (ja) * 2020-06-01 2023-07-04 エーエルエックス オンコロジー インコーポレイテッド 低メチル化剤を含むがんを治療するための併用療法
WO2022120286A1 (en) * 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
WO2025222106A1 (en) * 2024-04-18 2025-10-23 Aktis Oncology, Inc. Decoy miniproteins, compositions, & methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US20030118997A1 (en) * 2001-08-10 2003-06-26 Genset, S.A. Human cDNAs and proteins and uses thereof
US7074891B2 (en) * 2003-02-07 2006-07-11 Posco Leukocyte stimulating peptides
AU2006312148B2 (en) 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
AU2007235413B2 (en) 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20090068195A1 (en) * 2007-04-23 2009-03-12 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
BRPI0923442A2 (pt) * 2008-12-19 2016-01-12 Novartis Ag polipeptídeos solúveis para uso em tratamento de distúrbio autoimunes e inflamatórios.
DK2429574T3 (da) * 2009-05-15 2015-06-22 Univ Health Network Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen
BR112013027224A8 (pt) * 2011-04-22 2018-08-14 Emergent Product Dev Seattle Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
ME03550B (me) * 2012-12-17 2020-07-20 Trillium Therapeutics Inc Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama
WO2016023040A1 (en) * 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
DK3298043T3 (da) * 2015-05-18 2021-02-15 Ab Initio Biotherapeutics Inc SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
RU2740672C2 (ru) * 2015-08-07 2021-01-19 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
EA034582B1 (ru) * 2015-08-07 2020-02-21 АЭлЭкс ОНКОЛОДЖИ ИНК. Конструкции варианта sirp-альфа и их применение
WO2018118887A1 (en) * 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
EP3936526A4 (en) * 2019-03-06 2023-03-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE THEREOF

Similar Documents

Publication Publication Date Title
JP7662635B2 (ja) 抗ｐｄ－１－抗ｖｅｇｆａ二重特異性抗体、その医薬組成物および使用
JP7487112B2 (ja) Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用
US12384850B2 (en) Guidance and navigation control proteins and method of making and using thereof
JP2025078629A5 (enExample)
TWI874613B (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
IL268836B1 (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
IL312224B1 (en) Guidance and navigation control proteins and method of making and using thereof
JP2019500892A5 (enExample)
RU2018145961A (ru) Комбинированная терапия
JP2021513961A5 (enExample)
CA2963696A1 (en) Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
RU2018105963A (ru) Антитело против глипикана-3 и его применение
JP2020530306A5 (enExample)
CN115232209A (zh) 靶向gprc5d的抗体及其用途
US20180312606A1 (en) Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell
RU2020122822A (ru) Биспецифичные связывающие cd16 молекулы и их применение при лечении заболеваний
JP2021505637A5 (enExample)
US20250236864A1 (en) CAR LIBRARY AND scFv MANUFACTURING METHOD
WO2023201254A1 (en) T-cell engaging polypeptides and methods of use thereof
JP2020525432A (ja) 非対称ヘテロ二量体ＦＣ−ＳＣＦＶ融合抗ＧＬＯＢＯ Ｈおよび抗ＣＤ３二重特異的抗体およびがん療法（ｃａｎｅｒ ｔｈｅｒａｐｙ）におけるその使用
CN115298219A (zh) 多特异性抗体在治疗数个疾病方面的用途
CA3221115A1 (en) Treatment of pd-l1 negative or low expressing cancer with anti-icos antibodies
JP2023518835A (ja) 制御性ｔ細胞の除去用の二重特異性融合タンパク質
RU2020126486A (ru) Вариантные связывающие cd3 домены и их применение в комбинированной терапии при лечении заболеваний
RU2002128721A (ru) Многофункциональные полипептиды, содержащие сайт связывания с эпитопом nkg2d-рецепторного комплекса